Multi Strain Smoke Report Episode 2 featuring Yeti OG & The Sauce

The Multi Strain Smoke Report Episode 2 provides an informal overview of two cannabis strains—Yeti OG and The Sauce—through the lens of a user’s personal experience. While the report highlights sensory and experiential aspects of these strains, it does not offer clinical or medical guidance. This article aims to provide a factual, evidence-based summary of the information presented, with a focus on the safety, potency, and route of use of cannabis strains, particularly for patients and carers considering their use.

Key takeaways

• The report describes Yeti OG as an indica-dominant strain with high THC and moderate CBD levels, typically over 20% THC and 3% CBD.
• The Sauce is a newer strain with a citrusy, strawberry-orange aroma, bred with UK genetics, though its exact genetic composition is not disclosed.
• Both strains are reported to produce strong effects, with Yeti OG described as indica-led and The Sauce offering a more uplifting experience.
• The report does not provide clinical or medical advice, nor does it address the safety or efficacy of these strains for therapeutic use.

Evidence base

The information provided in the report is based on the personal experience of the reviewer, who tested both strains through smoking and vaping. There is no clinical data or peer-reviewed research cited to support the claims made about the effects, potency, or safety of these strains. The report mentions that Yeti OG is bred by Loompa Farms and is part of the Kush Family Collective, but no official documentation or regulatory information is provided regarding its cultivation, labelling, or medical use. Similarly, The Sauce is described as a strain bred by DJ Plants Man and grown by the Dead Fox Collective, but no evidence is given about its regulatory status, potency testing, or clinical applications.

The report also highlights the difference in sensory experience between smoking and vaping, noting that the full flavour profile of The Sauce is better appreciated through vaping. However, there is no discussion of the health implications of these different routes of administration, nor any mention of the potential risks associated with cannabis use, such as respiratory effects, cognitive impairment, or dependency. The absence of clinical evidence means that the information provided should not be used as a basis for medical decisions.

What patients should know

The report offers a subjective account of the sensory and experiential aspects of two cannabis strains, but it does not provide any medical or clinical information. Patients and carers should be aware that the information presented is not based on scientific research or clinical trials. The potency of cannabis strains, such as Yeti OG’s reported 20% THC, can vary significantly depending on the source, cultivation methods, and testing procedures. Without access to lab reports or official strain profiles, it is difficult to assess the actual potency or safety of these products.

The route of use—whether smoking or vaping—can also affect the experience and potential health risks. Smoking cannabis can lead to respiratory issues, while vaping may carry its own risks, including lung damage and exposure to harmful chemicals. The report does not address these risks, so patients should be cautious and consult with a healthcare professional before using any cannabis product.

For patients considering cannabis for medical use, it is important to understand that the effectiveness and safety of a strain depend on individual factors, including the condition being treated, the dosage, and the method of administration. The report does not provide any guidance on how to determine the appropriate strain, dosage, or method for a specific medical need. Patients should seek advice from a qualified clinician to ensure that their use is both safe and effective.

When to speak to a clinician

Patients and carers should consult a healthcare professional before using any cannabis product, especially if they have a pre-existing medical condition, are taking other medications, or are pregnant or breastfeeding. Cannabis can interact with certain medications and may have unintended side effects. It is important to discuss the potential benefits and risks of using cannabis for a specific condition.

Red flags or review points to consider when speaking to a clinician include:

• A history of mental health conditions, such as psychosis or depression
• A history of substance use disorders
• The presence of chronic respiratory conditions, such as asthma or COPD
• The use of other medications that may interact with cannabis
• Any changes in mood, behaviour, or cognitive function following cannabis use

A clinician can help assess the appropriateness of cannabis use, recommend the most suitable strain and method of administration, and monitor for any adverse effects.

Questions to ask a clinician

• What are the potential benefits and risks of using cannabis for my specific condition?
• How can I determine the appropriate strain, dosage, and method of administration for my needs?
• Are there any interactions between cannabis and the medications I am currently taking?

Source trail

• The report is based on the personal experience of the reviewer and does not include clinical or scientific evidence.
• No official guidance or regulatory information is provided regarding the strains described.
• Patients should refer to official sources such as the NHS, NICE, or the MHRA for information on cannabis use and safety.